27 results on '"MARSHALL, J. L."'
Search Results
2. Which adjuvant systemic treatments (AdjRx) would medical oncologists (MOs) wish to receive if they had colon cancer (CCa)? A survey of 150 physicians
3. Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
4. A phase 1 trial of GMX1777: An inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)
5. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
6. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC)
7. A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer
8. Pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of docetaxel (Doc) and oxaliplatin (Ox) in patients (Pts) with advanced solid tumors
9. A phase I trial of bexarotene and docetaxel in patients with advanced solid tumors
10. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors
11. A phase I study of TPI287: A third generation taxane administered weekly in patients with advanced cancer
12. A Q7D phase I study of TPI 287, a novel taxane, in advanced malignancies: Imaging studies, pharmacokinetics (PK) and circulating tumor cell (CTC) quantitation
13. A phase I study of the pan-Bcl2 family inhibitor GX15–070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas
14. Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101
15. First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I):poly(C), in patients with liver metastases from various primary cancers
16. A phase I trial of bexarotene and docetaxel in patients with advanced solid tumors
17. A phase I and pharmacokinetic (PK) study of docetaxel (DOC) and oxaliplatin (OX)
18. Extended survival in second-line pancreatic cancer after therapeutic vaccination
19. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors
20. Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors
21. A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
22. AG879, a c-erbB2 tyrosine kinase inhibitor, causes G1 arrest in pancreas cancer cells through p27Kipl independent transcriptional repression of cyclin Dl
23. Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors
24. A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
25. Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors
26. AG879, a c-erbB2 tyrosine kinase inhibitor, causes G1 arrest in pancreas cancer cells through p27Kipl independent transcriptional repression of cyclin Dl
27. An alternate method to overcoming central venous catheter blockage in patients receiving high-dose fluorouracil and leucovorin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.